Skip to main content
. Author manuscript; available in PMC: 2022 Jun 29.
Published in final edited form as: Vaccine. 2021 Jun 8;39(29):3974–3982. doi: 10.1016/j.vaccine.2021.05.056

Figure 1. Flow diagram of inclusion and exclusion criteria for study cohort.

Figure 1.

OLDW = OptumLabs Data Warehouse; ICD = International Classification of Disease; HZ = Herpes zoster; RZV = Recombinant Zoster Vaccine

a Index date was defined as the date at which an individual was eligible for study inclusion.

b Two valid doses of recombinant zoster vaccine were defined as receiving the second dose between 30 and 210 days after the first dose.